Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera Therapeutics appoints Christopher Hite to Board of Directors
Filed March 9, 2026 · Period ending March 5, 2026 · ~1 min read
Key Changes
-
low
Christopher Hite appointed as Class III Director effective March 5, 2026, with term expiring at 2027 Annual Meeting. Appointment expands Board oversight.
Item 5.02 verify on EDGAR → -
low
Hite receives standard new director compensation: stock options for 24,937 shares at $38.85 exercise price, vesting monthly over three years, plus $45,000 annual cash retainer (pro-rated for 2026).
Item 5.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade VERA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify